Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM

Renaissance Technologies LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 68,902 shares of the company’s stock, valued at approximately $1,507,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Nan Fung Trinity HK Ltd. raised its position in Immunome by 20.7% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after purchasing an additional 122,450 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Profund Advisors LLC increased its stake in shares of Immunome by 121.7% in the fourth quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after buying an additional 23,440 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Immunome in the fourth quarter valued at $1,611,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Immunome in the fourth quarter valued at $3,652,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IMNM has been the topic of several research reports. Truist Financial upped their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Leerink Partners lowered their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Wedbush boosted their target price on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Insider Buying and Selling at Immunome

In other Immunome news, Director Isaac Barchas sold 101,050 shares of Immunome stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the completion of the sale, the director owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total value of $2,273,555.44. Following the sale, the insider directly owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is currently owned by company insiders.

Immunome News Roundup

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Immunome Stock Up 6.6%

IMNM stock opened at $27.99 on Thursday. The company has a market cap of $3.17 billion, a P/E ratio of -11.06 and a beta of 2.08. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $28.04. The business has a fifty day moving average of $21.89 and a 200-day moving average of $22.20.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, equities research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.